Skip to content

QualityPoint Technologies News

Emerging Technologies News

Menu
  • About Us
  • Technology
  • Medical
  • Robots
  • Artificial Intelligence (AI)
  • 3D Printing
  • Contact Us
Menu

Huge Discount Offer: 14 ebooks + 2 courses

UK approves world-first CRISPR gene therapy “Casgevy” to cure sickle-cell disease

Posted on November 17, 2023

A new treatment for sickle-cell disease and transfusion-dependent β-thalassemia has been authorised by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for patients aged 12 and over after a rigorous assessment of its safety, quality and effectiveness.

Casgevy is the first medicine to be licensed that uses the innovative gene-editing tool CRISPR, for which its inventors were awarded the Nobel Prize in 2020.

Both sickle cell disease and β-thalassemia are genetic conditions caused by errors in the genes for haemoglobin, which is used by red blood cells to carry oxygen around the body. Sickle cell disease is particularly common in people with an African or Caribbean family background. β-thalassemia mainly affects people of Mediterranean, south Asian, southeast Asian and Middle Eastern origin.

In people with sickle cell disease, this genetic error can lead to attacks of very severe pain, serious and life-threatening infections, and anaemia (whereby your body has difficulty carrying oxygen).

In people with β-thalassaemia, it can lead to severe anaemia. Patients often need a blood transfusion every 3 to 5 weeks, and injections and medicines throughout their lives.

Casgevy is designed to work by editing the faulty gene in a patient’s bone marrow stem cells so that the body produces functioning haemoglobin. To do this, stem cells are taken out of bone marrow, edited in a laboratory and then infused back into the patient after which the results have the potential to be life-long.

In the clinical trial for sickle-cell disease, 45 patients have currently received Casgevy but only 29 patients have been in the trial long enough to be eligible for the primary efficacy interim analysis. Of these eligible patients, 28 (97%) were free of severe pain crises for at least 12 months after treatment.

In the clinical trial for transfusion-dependent β-thalassemia, 54 patients have currently received Casgevy but only 42 patients have been in the trial long enough to be eligible for the primary efficacy interim analysis. Of these, 39 (93%) did not need a red blood cell transfusion for at least 12 months after treatment. The remaining three had more than a 70% reduction in the need for red cell transfusions.

Side effects from treatment were similar to those associated with autologous (from a person’s own cells) stem cell transplants, including (but not limited to) nausea, fatigue, fever and increased risk of infection.

No significant safety concerns were identified during the trials. Safety continues to be closely monitored by the MHRA and the manufacturer.

Both trials are ongoing and further results will be made available in due course.

Casgevy is administered by taking stem cells out of a patient’s bone marrow and editing a gene in the cells in a laboratory. Patients must then undergo conditioning treatment to prepare the bone marrow before the modified cells are infused back into the patient. After that, patients may need to spend at least a month in a hospital facility while the treated cells take up residence in the bone marrow and start to make red blood cells with the stable form of haemoglobin.

The decision to authorise Casgevy has been endorsed by the UK government’s independent scientific advisory committee, the Commission on Human Medicines, after a robust review of the available evidence.

News Source: UK Gov

Share

Related News:

  1. 5 Children get 3D-printed Lab-Made Ears Grown From Their Own Cells
  2. A wearable system to monitor the stomach’s activity throughout the day
  3. Calcium-based MRI sensor enables more sensitive brain imaging
  4. Latest 10 Inventions using CRISPR gene Editing
Master RAG ⭐ Rajamanickam.com ⭐ Bundle Offer ⭐ Merch ⭐ AI Course

  • Bundle Offer
  • Hire AI Developer

Latest News

  • ​Firebase Studio: Google’s New Platform for Building AI-Powered Applications April 11, 2025
  • MIT Researchers Develop Framework to Enhance LLMs in Complex Planning April 7, 2025
  • MIT and NVIDIA Unveil HART: A Breakthrough in AI Image Generation March 25, 2025
  • Can LLMs Truly Understand Time Series Anomalies? March 18, 2025
  • Can AI tell us if those Zoom calls are flowing smoothly? March 11, 2025
  • New AI Agent, Manus, Emerges to Bridge the Gap Between Conception and Execution March 10, 2025
  • OpenAI Unveils GPT-4.5, Promising Enhanced AI Performance February 28, 2025
  • Anthropic Launches Claude Code to Revolutionize Developer Productivity February 25, 2025
  • Google Unveils Revolutionary AI Co-Scientist! February 24, 2025
  • Microsoft’s Majorana 1 Chip: Revolutionizing Quantum Computing with Topological Core Architecture February 20, 2025

Pages

  • About Us
  • Basics of 3D Printing
  • Key Innovations
  • Know about Graphene
  • Privacy Policy
  • Shop
  • Contact Us

Archives

Developed by QualityPoint Technologies (QPT)

QPT Products | eBook | Privacy

Timesheet | Calendar Generator

©2025 QualityPoint Technologies News | Design: Newspaperly WordPress Theme
Menu
  • About Us
  • Technology
  • Medical
  • Robots
  • Artificial Intelligence (AI)
  • 3D Printing
  • Contact Us